Lava gains after Janssen selects cancer therapy candidate for partnership

LAVA Therapeutics NV

02/06/2023 11:01

** Shares of cancer drug developer Lava Therapeutics NV
 LVTX.O  rise 35.8% to $2.58 premarket
    ** Co says Janssen Biotech Inc of Johnson & Johnson  JNJ.N 
has chosen a lead candidate for clinical development under
collaboration agreement with co
    ** LVTX has a research collaboration and license agreement
with Janssen for discovery and development of certain type of
antigen-based therapies to treat cancer
    ** LVTX is eligible to receive potential development,
regulatory and commercialization milestone payments and tiered
royalties
    ** Janssen will be responsible for future clinical
development, manufacture, and sales of the candidate at co’s
sole expense
    ** LVTX down ~46% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))